Patrick J. McEnany - 13 Nov 2024 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Director, Chairman of Board of Directors
Signature
/s/ Patrick J. McEnany
Issuer symbol
CPRX
Transactions as of
13 Nov 2024
Net transactions value
-$2,611,272
Form type
4
Filing time
15 Nov 2024, 17:00:11 UTC
Previous filing
13 Nov 2024
Next filing
21 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $327,450 +92,500 +2.1% $3.54 4,570,669 13 Nov 2024 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $2,125,465 -92,500 -2% $22.98 4,478,169 13 Nov 2024 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $158,079 +44,655 +1% $3.54 4,522,824 14 Nov 2024 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $971,336 -44,655 -0.99% $21.75 4,478,169 14 Nov 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -92,500 -4.4% $0.000000 2,008,245 13 Nov 2024 Common Stock 92,500 $3.54 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -44,655 -2.2% $0.000000 1,963,590 14 Nov 2024 Common Stock 44,655 $3.54 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold for personal reasons, including paying federal income taxes and diversifying the Reporting Person's portfolio. Shares were not sold as a result of any disagreement with the Company. Mr. McEnany remains the non-executive chairman of the Company's Board of Directors and the Company's largest individual, non-institutional shareholder.
F2 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $22.82 to $23.13 per share.
F3 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $21.52 to $22.20 per share.
F4 Options vested in three equal tranches on May 29, 2019, 2020 and 2021.